Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.

DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V

The Journal of clinical endocrinology and metabolism1 Feb 2020Cited by 43 (Europe PMC)

PMID31769496DOI10.1210/clinem/dgz072PepBankPUB-31769496

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, semaglutide 0.5 mg reduced HbA1c from baseline across race and ethnicity subgroups of the SUSTAIN trials.
In plain wordsIn adults with type 2 diabetes, semaglutide 0.5 mg lowered HbA1c in every race and ethnicity group studied.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction by race and ethnicity subgroup, semaglutide 0.5 mg
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
HbA1c reduction
1 to 1.5 percentage points
0.5 mg across subgroups
Source sentences
Summary
HbA1c was reduced from baseline by 1.0 to 1.5 percentage points and 1.3 to 2.0 percentage points, and body weight was reduced by 2.3 to 4.7 kg and 3.6 to 6.1 kg with semaglutide 0.5 and 1.0 mg, respectively, across race and ethnicity subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, semaglutide 1.0 mg reduced HbA1c from baseline across race and ethnicity subgroups of the SUSTAIN trials.
In plain wordsIn adults with type 2 diabetes, semaglutide 1.0 mg lowered HbA1c in every race and ethnicity group studied.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction by race and ethnicity subgroup, semaglutide 1.0 mg
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Measurements
HbA1c reduction
1.3 to 2 percentage points
1.0 mg across subgroups
Source sentences
Summary
HbA1c was reduced from baseline by 1.0 to 1.5 percentage points and 1.3 to 2.0 percentage points, and body weight was reduced by 2.3 to 4.7 kg and 3.6 to 6.1 kg with semaglutide 0.5 and 1.0 mg, respectively, across race and ethnicity subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949602
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, semaglutide 0.5 mg reduced body weight from baseline across race and ethnicity subgroups of the SUSTAIN trials.
In plain wordsIn adults with type 2 diabetes, semaglutide 0.5 mg lowered body weight in every race and ethnicity group studied.
Peptide
Semaglutide
Outcome
DecreaseBody weight reduction by race and ethnicity subgroup, semaglutide 0.5 mg
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
Body weight reduction
2.3 to 4.7 kg
0.5 mg across subgroups
Source sentences
Summary
HbA1c was reduced from baseline by 1.0 to 1.5 percentage points and 1.3 to 2.0 percentage points, and body weight was reduced by 2.3 to 4.7 kg and 3.6 to 6.1 kg with semaglutide 0.5 and 1.0 mg, respectively, across race and ethnicity subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949603
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, semaglutide 1.0 mg reduced body weight from baseline across race and ethnicity subgroups of the SUSTAIN trials.
In plain wordsIn adults with type 2 diabetes, semaglutide 1.0 mg lowered body weight in every race and ethnicity group studied.
Peptide
Semaglutide
Outcome
DecreaseBody weight reduction by race and ethnicity subgroup, semaglutide 1.0 mg
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Measurements
Body weight reduction
3.6 to 6.1 kg
1.0 mg across subgroups
Source sentences
Summary
HbA1c was reduced from baseline by 1.0 to 1.5 percentage points and 1.3 to 2.0 percentage points, and body weight was reduced by 2.3 to 4.7 kg and 3.6 to 6.1 kg with semaglutide 0.5 and 1.0 mg, respectively, across race and ethnicity subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949604
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in the SUSTAIN trials, minor changes in blood pressure were observed with semaglutide.
In plain wordsIn adults with type 2 diabetes, semaglutide was followed by only minor changes in blood pressure.
Peptide
Semaglutide
Outcome
Direction not reportedBlood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Minor changes in blood pressure and lipid profiles were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949605
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in the SUSTAIN trials, minor changes in lipid profiles were observed with semaglutide.
In plain wordsIn adults with type 2 diabetes, semaglutide was followed by only minor changes in blood lipids.
Peptide
Semaglutide
Outcome
Direction not reportedLipid profiles
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Minor changes in blood pressure and lipid profiles were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949606
07HumanRandomized controlled trialSafety outcome
In the SUSTAIN trials, adverse events were reported in similar proportions of subjects across trials.
In plain wordsIn the SUSTAIN trials, side effects were reported in similar shares of people across the trials.
Peptide
Semaglutide
Outcome
No significant changeAdverse events across trials
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Adverse events (AEs) were reported in similar proportions of subjects across trials.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949607
08HumanRandomized controlled trialSafety outcome
In the SUSTAIN trials, more Asian subjects than subjects of other race subgroups discontinued treatment prematurely due to adverse events.
In plain wordsIn the SUSTAIN trials, more Asian participants than other groups stopped treatment early because of side effects.
Peptide
Semaglutide
Outcome
IncreaseDiscontinuation due to adverse events in Asian subjects
Study
n: not reported in source
Comparator
Other race subgroups
Outcome group
Adverse events · Whole body
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
More Asian versus other race subgroups discontinued treatment prematurely due to AEs.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949608
09HumanRandomized controlled trialSafety outcome
In the SUSTAIN trials, the most commonly reported adverse events were gastrointestinal disorders.
In plain wordsIn the SUSTAIN trials, the most common side effects were stomach and gut problems.
Peptide
Semaglutide
Outcome
Not applicableMost common adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The most commonly reported AEs were gastrointestinal disorders.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials.
Summary · context
Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).
Report a problemFND-3176949609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials7

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

7 trials · 7 completed · 7 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02648204